Murali Prahalad Net Worth

The estimated Net Worth of Murali Prahalad is at least $263 Tisíc dollars as of 24 November 2020. Murali Prahalad owns over 18,000 units of Maravai Lifesciences stock worth over $262,996 and over the last 4 years Murali sold MRVI stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Murali Prahalad MRVI stock SEC Form 4 insiders trading

Murali has made over 1 trades of the Maravai Lifesciences stock since 2020, according to the Form 4 filled with the SEC. Most recently Murali bought 18,000 units of MRVI stock worth $486,000 on 24 November 2020.

The largest trade Murali's ever made was buying 18,000 units of Maravai Lifesciences stock on 24 November 2020 worth over $486,000. On average, Murali trades about 3,000 units every 0 days since 2020. As of 24 November 2020 Murali still owns at least 29,852 units of Maravai Lifesciences stock.

You can see the complete history of Murali Prahalad stock trades at the bottom of the page.

What's Murali Prahalad's mailing address?

Murali's mailing address filed with the SEC is C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO, CA, 92121.

Insiders trading at Maravai Lifesciences

Over the last 4 years, insiders at Maravai Lifesciences have traded over $97,620,365 worth of Maravai Lifesciences stock and bought 174,388 units worth $4,706,376 . The most active insiders traders include Investment Xi Llcmaravai Li..., Gregory T Lucier a Robert B Hance. On average, Maravai Lifesciences executives and independent directors trade stock every 142 days with the average trade being worth of $9,901,814. The most recent stock trade was executed by Investment Xi Llcmaravai Li... on 28 May 2024, trading 9,940,974 units of MRVI stock currently worth $97,620,365.

What does Maravai Lifesciences do?

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry, immunofluorescence, and glycobiology. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

Complete history of Murali Prahalad stock trades at Maravai Lifesciences

Maravai Lifesciences executives and stock owners

Maravai Lifesciences executives and other stock owners filed with the SEC include:

• Carl W. Hull,
  Co-Founder, Chairman & CEO
• Brian Neel,
  Chief Operating Officer of Nucleic Acid Production
• Christine Dolan,
  Chief Operating Officer of Biologics Safety Testing
• Doreen Pippen,
  VP of Marketing
• Kurt Oreshack,
  VP, Gen. Counsel & Sec.
• Debra Hart,
  Sr. Director of Investor Relations
• Kevin M. Herde,
  Exec. VP & CFO
• John A De Ford,
  Director
• Jessica Hopfield,
  Director
• Gregory T Lucier,
  Director
• Benjamin James Daverman,
  Director
• Constantine S Mihas,
  Director
• Luke Joseph Marker,
  Director
• Sean Laurence Cunningham,
  Director
• Peter Michael Leddy,
  See Remarks
• Kevin Herde,
  Chief Financial Officer
• Christine Dolan,
  See Remarks
• Brian Neel,
  See Remarks
• Kurt Oreshack,
  General Counsel
• Investment Xi Llcmaravai Li...,
  
• Susannah Gray,
  Director
• Robert B Hance,
  Director
• Anat Ashkenazi,
  Director
• Lisa Sellers,
  See Remarks
• Eric Tardif,
  President
• Murali Prahalad,
  Director
• Carl Hull,
  See Remarks
• Andrew Burch,
  See Remarks
• Investment Xi Llcmaravai Li...,
  
• Rebecca Buzzeo,
  See Remarks
• William E. Iii Martin,
  Chief Executive Officer